Moderna claims 3 months of Omicron booster response: According to Moderna Inc., the Covid-19 vaccination booster, which targets the Omicron BA.1 subvariant, produced a robust immune response against that variant, with antibody levels remaining high for at least three months.
In several countries, Pfizer Inc. and Moderna’s omicron-tailored injections have already approved by the government. In addition, the US has also given the green light to booster shots meant to protect against the BA.4 and BA.5 subvariants of Omicron that are currently in circulation.
Moderna CEO Stephane Bancel stated, “clinical trial data currently suggests that the better immune response elicited by our bivalent booster has endurance for at least three months.”
Later this year, according to Moderna, results from the targeted BA.4/BA.5 vaccine’s human trials will be available.